Share:
San Francisco-headquartered
Invitae Corp (NYSE: NVTA) defines itself as medical genetics company seeking to bring comprehensive genetic information into mainstream medicine, with the goal of improving outcomes and lowering health care expenses.
Admittedly, this is not an easy task and according to CEO Sean George, it's even more difficult than it sounds.
Dollars And Sense: “There are a lot of reasons that genetics hasn't become front and center in mainstream medicine, and none of them are particularly good,” he admitted in an interview with Benzinga. “We can break it down into two main buckets: cost and access.”
In terms of costs, George explained Invitae has “invested heavily in reducing the cost dramatically of getting this information, and more importantly translating that information to actionable medical results.”